Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Juno Therapeutics

Juno Therapeutics
2013 FOUNDED
M&A STATUS
601-700 EMPLOYEES
M&A LATEST DEAL TYPE
$10.4B LATEST DEAL AMOUNT
Description

Juno Therapeutics Inc is a US-based biopharmaceutical company. It is focused on developing cellular immunotherapies for the treatment of cancer. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. The product pipeline of the company consists of the therapeutics for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, lung cancer, mesothelioma, multiple myeloma, neuroblastoma, Non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer and triple-negative breast cancer. The company primarily derives revenue from the collaboration and license agreements.

Formerly Known As
FC Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Therapeutic Devices
Acquirer
Primary Office
  • 400 Dexter Avenue North
  • Suite 1200
  • Seattle, WA 98109
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Juno Therapeutics’s full profile, request a free trial.

Juno Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 06-Mar-2018 $10.4B 00.000 000.00 Completed Generating Revenue/Not Profitable
7. Secondary Transaction - Open Market 01-Sep-2017 00000 00.000 00.000 Completed Generating Revenue/Not Profitable
6. 2PO 14-Sep-2015 00.000 Completed Generating Revenue/Not Profitable
5. PIPE 29-Jun-2015 000 00.000 000 Completed Clinical Trials - Phase 2
4. IPO 02-Jan-2015 00000 00000 00.000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 01-Aug-2014 00000 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 24-Apr-2014 $176M $183M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A1) 26-Dec-2013 $6.67M $6.67M Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Juno Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A2 00,000,000 00.000000 00 00 00 00 00 00.000
Series A1 9,000,000 $0.000100 8% $1 $1 1x $1 2.27%
Series A 87,722,673 $0.000100 8% $1 $1 1x $1 22.15%
To view this company’s complete Cap Table, request access »

Juno Therapeutics Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Venture Capital-Backed Philadelphia, PA 0000 00000000000 0000
000000000 Formerly VC-backed Rockville, MD 000 00000 00000000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
0000000 Venture Capital-Backed Cambridge, MA 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Juno Therapeutics Investments & Acquisitions (7)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00 000000000000 07-Mar-2018 00000 00000 00 0000 Biotechnology 0000 000000
00000000000000 14-Jul-2016 000000000000000000 0000 Pharmaceuticals
0000000 11-Jan-2016 000000000000000000 00000 Discovery Tools (Healthcare)
00 000000000000 01-Jan-2016 00000 0000000 Biotechnology 0000 000000
X BODY 01-Jun-2015 Merger/Acquisition 00000 Biotechnology 0000 000000
To view this company’s complete investment and acquisition history, request access »

Juno Therapeutics Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Alaska Permanent Fund Sovereign Wealth Fund Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
Bezos Expeditions Family Office Minority 000 0000 000000 0
Biomark Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

Juno Therapeutics Executive Team (34)

Name Title Board
Seat
Contact
Info
Lothar Germeroth Ph.D Managing Director & Senior Vice President
Cindy Elkins Chief Information Officer
Hyam Levitsky MD Chief Scientific Officer & Executive Vice President
Michail Sitkovsky Ph.D Scientific Consultant
Sangwook Choi Ph.D Quality Engineer

9 Former Executives

You’re viewing 5 of 34 executives. Get the full list »

Juno Therapeutics Board Members (7)

Name Representing Role Since Contact
Info
Hal Barron Self Board Member 000 0000
Howard Pien Self Chairman 000 0000
Marc Tessier-Lavigne Ph.D Self Board Member 000 0000
Mary Agnes Wilderotter Self Board Member 000 0000
Richard Klausner MD Self Co-Founder & Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »